Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters (NYSE: WAT) announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling U.S. commercialization for bloodstream infection and sepsis diagnostics. Clinical data showed a ~3-hour (~15%) faster mean time to detection versus the prior BD BACTEC FX system.
The fully automated platform offers automated gravimetric vial volume measurement, up to 60-vial automated loading (50% more than the leading competitor), and 480- or 960-vial configurations. The system is also available in Europe and Japan following CE marking and PMDA licensing.
Waters (NYSE: WAT) unveiled the Xevo MRT P10 Mass Spectrometer, a benchtop high-resolution QToF system for high-throughput multiomics, bioanalysis, and biopharma labs. It delivers up to 20x higher MS/MS sensitivity and 2x faster acquisition than its predecessor, with advanced acquisition modes.
According to Waters, the system supports targeted and untargeted LC‑MS/MS, identifies up to 40% more lipids than a leading alternative, and, with the DESI XS source, enables MS imaging up to 200 Hz with six-fold higher throughput. Global availability is expected in summer 2026.
Waters (NYSE: WAT) launched the Cyclic IMS P20 Mass Spectrometer, a high-resolution structural and spatial omics platform unveiled at ASMS 2026. It combines multipass Cyclic Ion Mobility Spectrometry with advanced fragmentation, probing, and imaging to enhance early disease signal detection and biotherapeutic development.
The system delivers >10x higher MS/MS sensitivity than its predecessor, a >50% extended upper mass range to >100 kDa, and integrates MALDI XS and DESI XS imaging. Global availability is expected from September 2026.
Waters (NYSE:WAT) announced that President and CEO Udit Batra, Ph.D., will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET.
A live webcast and 90-day replay will be available on Waters' investor relations site.
Waters Corporation (NYSE: WAT) reported Q1 2026 revenue of $1.267 billion, above guidance by $56 million, driven by $747 million organic revenue (13% as reported, 11% cc) and $520 million from the acquired Biosciences and Diagnostic Solutions businesses. Adjusted EPS was $2.70 (+20% YoY); GAAP EPS was a loss of $0.87 reflecting acquisition accounting. The company raised full‑year organic growth guidance to 6.5–8.0% and adjusted EPS guidance to $14.40–$14.60, and now expects acquired business revenue of $3.035 billion in 2026.
Waters Corporation (NYSE:WAT) will report Q1 2026 results and host a conference call on May 5, 2026 at 8:30 a.m. ET.
A live webcast will be available on Waters Investor Relations, and a replay will remain available through at least June 2, 2026.
Waters (NYSE: WAT) launched the omniDAWN Multi-Angle Light Scattering (MALS) Photometer, the first extended-range MALS detector for UHPLC/UPLC workflows, available globally in summer 2026. The 18-angle detector enables up to 4x faster run times, 10x extended sizing (~50–500 nm radius), and reduces sample use by 30–50% and solvent use by ~40%.
Powered by ASTRA Software and integrating UV and RI detection, omniDAWN delivers absolute molar mass and size measurements for aggregates, viral vectors, LNPs, ADCs, and advanced materials; Empower compatibility is planned later this year.
Waters (NYSE: WAT) announced U.S. FDA clearance (April 8, 2026) of the Onclarity HPV Self-Collection Kit and FDA approval of the BD Onclarity HPV Assay for at-home use. The assay provides extended genotyping (six individual types, three pooled groups) and works with the automated BD COR System.
The kit aims to increase screening access for unscreened or under-screened individuals (about 60% of cervical cancer cases) and will be available by prescription in coming months, covered by private insurance, Medicaid, and Medicare.
Waters (NYSE: WAT) priced a $3.5 billion offering of senior notes issued by subsidiary Augusta SpinCo, split across five tranches maturing 2027, 2029, 2031, 2033 and 2036 with coupon rates from 4.321% to 5.245% at 100% issue price.
Proceeds, together with cash on hand, are intended to repay the $3.5 billion delayed draw term loan; closing expected on or about March 23, 2026, subject to customary conditions.
Waters (NYSE: WAT) launched the ARES-G3 Rheometer on March 9, 2026, a next-generation TA Instruments product that boosts data capture and speeds up testing.
The instrument captures up to 25,000 data points per second, delivers up to 10x the data rate of its predecessor, and can cut standard test times by up to 80%, enabling faster workflows and reduced calibrations.